Ondine Biomedical Inc. (OBI) is a Biotechnology company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Ondine Biomedical Inc. in 2026. The next earnings report is expected on September 29, 2026.
Next earnings date
29 Sep 2026
In 40 days
EPS estimate
—
Revenue estimate
324.4K
Past earnings
No dividend history available.
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
Ondine Biomedical Inc. (OBI) is scheduled to report earnings on September 29, 2026.
Ondine Biomedical Inc. (OBI) last reported earnings on May 15, 2025.
Ondine Biomedical Inc. (OBI) is listed on London Exchange.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.